Despite this limitation, a trend favoring the use of these drugs remains apparent, particularly for selective COX-2 inhibition with coxibs in patients with colorectal, liver and biliary tract, lymphohematopoietic and lung cancers, as well as male patients with prostate, and head and neck cancer, and female patients with breast cancer. The gene discussed is PTGS2; the disease is lung carcinoma.